First Time Loading...

Eagle Pharmaceuticals Inc
NASDAQ:EGRX

Watchlist Manager
Eagle Pharmaceuticals Inc Logo
Eagle Pharmaceuticals Inc
NASDAQ:EGRX
Watchlist
Price: 4.41 USD 0.23% Market Closed
Updated: May 6, 2024

Eagle Pharmaceuticals Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eagle Pharmaceuticals Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Eagle Pharmaceuticals Inc
NASDAQ:EGRX
Operating Income
$36.1m
CAGR 3-Years
65%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$8.7B
CAGR 3-Years
24%
CAGR 5-Years
1%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is Eagle Pharmaceuticals Inc's Operating Income?
Operating Income
36.1m USD

Based on the financial report for Jun 30, 2023, Eagle Pharmaceuticals Inc's Operating Income amounts to 36.1m USD.

What is Eagle Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-8%

Over the last year, the Operating Income growth was -54%. The average annual Operating Income growth rates for Eagle Pharmaceuticals Inc have been 65% over the past three years , -8% over the past five years .